Fast Five Quiz: Metastatic Hormone-Sensitive Prostate Cancer Treatment

Bradley Schwartz, DO; Daniel S. Schwartz, MD


June 27, 2022

Febrile neutropenia has been reported in 7% of patients receiving docetaxel chemotherapy plus ADT for mHSPC, per Cattrini and colleagues.

There is a high risk for myelosuppression with docetaxel. Therefore, it may be advisable to avoid docetaxel in patients at high risk for this complication.

Hypertension has been among the adverse effects observed with the anti-androgen therapies abiraterone and enzalutamide. A 2020 meta-analysis showed a moderate risk for hypertension among patients receiving abiraterone. Another meta-analysis from 2019 showed an increased risk for hypertension with enzalutamide.

In addition to hypertension and fatigue, apalutamide and enzalutamide may confer a small risk for seizures; however, no increase in the incidence of seizures has been observed in patients treated with enzalutamide who had a history of seizure or other risk factors in the UPWARD study.

Listen to an expert discuss the management of patients with mHSPC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.